Brain-derived neurotrophic factor (BDNF) as a new way to diagnose severe preeclampsia
AbstractThe aim of the study was to develop a method for diagnosing severe preeclampsia based on the determination of the quantitative content of brain-derived neurotrophic factor (BDNF) in blood serum.
Material and methods. The study included 91 pregnant women, including 80 women with various forms of hypertensive disorders [chronic arterial hypertension, gestational arterial hypertension, preeclampsia (moderate, severe], HELLP syndrome) – the study group. The comparison group consisted of 11 pregnant women without hypertensive disorders and without proteinuria. The control group consisted of 11 relatively healthy non-pregnant women, without signs of arterial hypertension. In the blood serum of pregnant women, the concentration of BDNF was determined by ELISA.
Results. In pregnant women with hypertensive disorders in the gestation period of 22–40 weeks, the level of BDNF in the serum of peripheral venous blood was determined. If its levels were ≥6.8 ng/ml the authors diagnosed severe preeclampsia, and at a value of 11.1 ng/ml, HELLP syndrome was diagnosed.
Keywords:pregnancy; preeclampsia; HELLP syndrome; brain-derived neurotrophic factor (BDNF)
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
For citation: Kondratyuk I.V., Padrul M.M., Karakulova Yu.V. Brain-derived neurotrophic factor (BDNF) as a new way to diagnose severe preeclampsia. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie [Obstetrics and Gynecology: News, Opinions, Training]. 2022; 10 (4): 13–7. DOI: https://doi.org/10.33029/2303-9698-2022-10-4-13-17 (in Russian)
REFERENCES
1. Maternal mortality in the Russian Federation in 2014. Methodological letter of the Ministry of Health of the Russian Federation dated 09.10.2015. 72 p. (in Russian)
2. Preeclampsia. Eclampsia. Edema, proteinuria and hypertensive disorders during pregnancy, childbirth and the postpartum period: Clinical guidelines (treatment protocol). Moscow, 2021: 40 p. (in Russian)
3. Radzinsky V.E., Fuks A.M. Obstetrics. Textbook. Moscow: GEOTAR-Media, 2016: 1040 p. (in Russian)
4. Serov V.N., Adamyan L.N., Shifman E.M. Hypertensive disorders during pregnancy, childbirth and the postpartum period. Clinical guidelines. Protocol. 2016: 7 p. (in Russian)
5. Gomazkov O.A. Pleiotropic effects of neurotrophins. Moscow: KDM, 2010: 136 p. (in Russian)
6. Tsepilov S.V., Karakulova Yu.V. Blood neurotrophins in chronic cerebral ischemia. Permskiy meditsinskiy zhurnal [Perm’ Medical Journal]. 2016; (6): 60–5. URL: https://permmedjournal.ru/PMJ/article/view/5942 (in Russian)
7. International Statistical Classification of Diseases and Related Health Problems, 10th revision. Geneva, 1995 (additions 2021). URL: https://mkb-10.com/
8. Kamilova M.Ya., et al. Early and late preeclampsia: the course of pregnancy, childbirth and perinatal outcomes. Vestnik Avitsenny [Avicenna Bulletin]. 2016; 4 (69): 34–8. (in Russian)
9. Karakulova Yu.V., Padrul’ M.M., Kondratyuk I.V. A method for predicting the risk of developing severe complications of preeclampsia. Patent of the Russian Federation (RU 2741730 C1). Patent holder of the Federal State Budgetary Educational Institution of Higher Education named after academician E.A. Wagner. 2020. Bull. No. 4. URL: https://findpatent.ru/patent/274/2741730.html (in Russian)
10. Henderson J.T., et al. Preeclampsia screening: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2017; 317 (16): 1668–83.
11. Kimura A., Namekata K., Guo X., Harada C., Harada T. Neuroprotection, growth factors and BDNF-TrkB signalling in retinal degeneration. Int J Mol Sci. 2016; 17 (9): E1584. DOI: https://doi.org/10.3390/ijms17091584 PMID: 27657046
12. Yamamoto H., Gurney M.E. Human platelets contain brain-derived neurotrophic factor. J Neurosci. 1990; 10 (11): 3469–78.